Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.63 |
| ▸ | NPY4R | P50391 | 8/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.63 |
| ▸ | NPY1R | P25929 | 6/20 | 0.63 |
| ▸ | TFPI | P10646 | 4/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.58 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.56 |
| ▸ | CALCR | P30988 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29360416 | 0.91 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30574250 | 0.89 | NPY2R (0.72) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30574249 | 0.89 | NPY2R (0.71) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29356625 | 0.89 | NPY2R (0.71) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29553166 | 0.85 | NPY2R (0.59) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30574247 | 0.84 | NPY2R (0.74) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29357353 | 0.84 | NPY2R (0.73) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29874441 | 0.84 | NPY2R (0.69) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30364495 | 0.82 | TFPI (0.68) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30262121 | 0.81 | CALCR (0.59) | NPY2RNPY4RNPY5RNPY1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220025003-A1 | REAGENTS AND METHODS FOR CONTROLLING PROTEIN FUNCTION AND INTERACTION | HOWARD HUGHES MEDICAL INSTITUTE | 2022-01-27 | — | — | US | claimed |
| US-12565665-B2 | Compositions and methods for controlled mRNA translation and stability | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-03-03 | — | — | US | disclosed |
| US-12559530-B2 | Regulated synthetic gene expression systems | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250243247-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250059243-A1 | REGULATED SYNTHETIC GENE ACTIVATION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-02-20 | — | — | US | disclosed |
| US-12202863-B2 | Chimeric antigen receptor (CAR) modulation | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2025006719-A2 | REGULATED SYNTHETIC GENE ACTIVATION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-01-02 | — | — | WO | disclosed |
| US-12180485-B2 | Repressible control of gene expression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240400639-A1 | ENGINEERED EXTRACELLULAR RECEPTOR CONSTRUCTS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240263193-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED MRNA TRANSLATION AND STABILITY | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-08-08 | — | — | US | disclosed |
| US-20230279406-A1 | INDUCIBLE CONTROL OF GENE EXPRESSION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-03 | — | — | US | disclosed |
| US-11660288-B2 | Drug-controlled systems and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-25 | — | — | US | disclosed |
| US-11572565-B2 | Inducible control of gene expression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-02-07 | — | — | US | disclosed |
| US-11530246-B2 | Regulated synthetic gene expression systems | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-12-20 | — | — | US | disclosed |
| CN-114375198-A | Regulated synthetic gene expression system | 波士顿大学董事会 | 2022-04-19 | — | — | CN | disclosed |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3969037-A2 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | Trustees of Boston University (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220025003-A1 | REAGENTS AND METHODS FOR CONTROLLING PROTEIN FUNCTION AND INTERACTION | HOWARD HUGHES MEDICAL INSTITUTE | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | NPY2R 3744/4885NPY4R 4444/4885NPY5R 4134/4885 |
| US-11660288-B2 | Drug-controlled systems and uses thereof | ATF4, MRPL21, SARS1 | NPY2R 2590/4885NPY4R 2348/4885NPY5R 3413/4885 |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | ATF4, MRPL21, TMPRSS2 | NPY2R 1912/4885NPY4R 1875/4885NPY5R 3050/4885 |
| US-12565665-B2 | Compositions and methods for controlled mRNA translation and stability | ADAR, ADA, NSUN2 | NPY2R 4475/4885NPY4R 4647/4885NPY5R 4832/4885 |
| US-20250059243-A1 | REGULATED SYNTHETIC GENE ACTIVATION SYSTEMS | BPTF, SRRT, TEAD3 | NPY2R 3899/4885NPY4R 4128/4885NPY5R 4196/4885 |
| US-20250243247-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | NPY2R 3151/4885NPY4R 3416/4885NPY5R 3573/4885 |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | NPY2R 3151/4885NPY4R 3416/4885NPY5R 3573/4885 |
| US-11530246-B2 | Regulated synthetic gene expression systems | SRRT, BPTF, MYCBP | NPY2R 3744/4885NPY4R 4444/4885NPY5R 4134/4885 |
| US-20220025003-A1 | REAGENTS AND METHODS FOR CONTROLLING PROTEIN FUNCTION AND INTERACTION | HAVCR2, GTF3C4, GTF3C1 | NPY2R 4705/4885NPY4R 4318/4885NPY5R 4571/4885 |
| US-12202863-B2 | Chimeric antigen receptor (CAR) modulation | HAVCR2, CPB1, CTRL | NPY2R 3151/4885NPY4R 3416/4885NPY5R 3573/4885 |
| US-20240263193-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED MRNA TRANSLATION AND STABILITY | ADAR, ADA, RNGTT | NPY2R 4866/4885NPY4R 4880/4885NPY5R 4868/4885 |
| US-12559530-B2 | Regulated synthetic gene expression systems | MECP2, ZMYND8, EED | NPY2R 2623/4885NPY4R 1341/4885NPY5R 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.